Integrated in silico investigation of an androstendiol derivative (monoxetanol) as a potential anti-prostate cancer agent: insights from molecular docking, MD simulations, MM/PBSA, ADMET, and DFT analyses
- 7 May 2026
- journal article
- Published by Springer Nature in In Silico Pharmacology
- Vol. 14 (2) , 134
Abstract
A novel androstendiol derivative, monoxetanol (MON), was synthesized from androsta-5,15-diene-3β-ol-17-one via a multistep route and evaluated for its anticancer potential. In vitro cytotoxicity was assessed using an MTT assay against human prostate cancer cell lines PC-3 and LNCaP-AI. MON exhibited marked cytotoxicity, with inhibition rates of 79.8% (PC-3) and 64.7% (LNCaP-AI) at 10.0 μM. To rationalize these effects and explore its therapeutic potential, an integrated in silico approach comprising molecular docking, ADMET prediction, molecular dynamics (MD) simulations, MM/PBSA binding free energy calculations, and density functional theory (DFT) analyses was performed, using abiraterone (ABT) as a reference. Docking results indicated that MON displayed consistently stronger binding affinities toward key oncogenic targets, including epidermal growth factor receptor (EGFR), cytochrome P450 17A1 (CYP17A1), and extracellular signal-regulated kinase 2 (ERK2). ADMET profiling suggested favorable pharmacokinetic properties and drug-likeness, with no major toxicity concerns. MD simulations confirmed the conformational stability of MON-protein complexes, supported by favorable MM/PBSA binding free energies predominantly driven by van der Waals and electrostatic contributions. Per-residue decomposition highlighted a broader and more favorable interaction network for MON, particularly within CYP17A1 and ERK2 active sites. DFT calculations further revealed a larger HOMO-LUMO energy gap for MON than ABT in both gas and aqueous phases, indicating enhanced chemical stability. Collectively, these findings position MON as a promising lead scaffold for further optimization and experimental validation in prostate cancer therapy. The online version contains supplementary material available at 10.1007/s40203-026-00626-3.Keywords
This publication has 50 references indexed in Scilit:
- Synthesis, In‐Silico Evaluation, ADME Analysis, and Molecular Dynamics Simulation of Novel β‐Lactam Derivatives Based on Diclofenac and Sulindac With Anticancer and Antioxidant ActivitiesChemistry & Biodiversity, 2025
- Antidiabetic Potential of Synthesized Ferrocenylmethylaniline Derivatives: Insights From In Vitro Studies, Molecular Docking, ADMET, DFT Calculations, and Molecular Dynamics SimulationBiotechnology and Applied Biochemistry, 2025
- Design, Synthesis, and Molecular Docking Studies of 2‐Azetidinone‐Based Combretastatin A‐4 Analogues with Anticancer ActivityChemistrySelect, 2025
- Exploring the Interactions of Ferrocenylmethylnucleobase Derivatives With BSA and HHb: Insights From Electrochemical, Spectroscopic, ADMET, in Silico Docking, and MD SimulationsChemistrySelect, 2025
- Synthesis, Antioxidant, and Antidiabetic Potential of Ferrocenylmethylnucleobase Compounds: In Vitro, In Silico Molecular Docking, DFT Calculation, and Molecular Dynamic SimulationsApplied Organometallic Chemistry, 2025
- New CYP17 Hydroxylase Inhibitors: Synthesis, Biological Evaluation, QSAR, and Molecular Docking Study of New Pregnenolone AnalogsArchiv der Pharmazie, 2014
- The Role of Fluorine Substitution in Biphenyl Methylene Imidazole‐Type CYP17 Inhibitors for the Treatment of Prostate CarcinomaChemMedChem, 2010
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- GROMACS: Fast, flexible, and freeJournal of Computational Chemistry, 2005
- Inhibition of CYP 17, a New Strategy for the Treatment of Prostate CancerArchiv der Pharmazie, 2002